Repare Therapeutics Q2 net loss narrows to $16.7 mln
Overview
Repare Therapeutics Q2 net loss narrows to $16.7 mln from $34.8 mln last year
Co entered worldwide licensing agreement with Debiopharm for lunresertib
Exploring strategic alternatives to maximize shareholder value
Outlook
Company expects Q4 2025 data from LIONS and POLAR trials
Repare exploring strategic alternatives to maximize shareholder value
Company anticipates milestone payments from Debiopharm licensing deal
Repare expects initial trial data in Q4 2025
Result Drivers
OUT-LICENSING - Out-licensed early-stage discovery platforms to DCx Biotherapeutics, resulting in a $5.7 mln gain
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS |
| -$0.39 |
|
Q2 Net Income |
| -$16.74 mln |
|
Q2 Income From Operations |
| -$17.78 mln |
|
Q2 Operating Expenses |
| $23.70 mln |
|
Q2 Pretax Profit |
| -$16.50 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Repare Therapeutics Inc is $5.00, about 69.6% above its August 7 closing price of $1.52
Press Release: ID:nBw2yZ68Qa
